Company Profile

Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.

Employees

255

Sector

Advanced Medical Equipment & Technology

More about the company

04-28	Singular Genomics Appoints John Stark as Chief Executive Officer	CI
04-28	Singular Genomics Systems, Inc. Announces Transition of Josh Stahl as Independent Director	CI
03-18	Singular Genomics and Vanderbilt University Medical Center Establish Center of Excellence to Advance High-Throughput Spatial Multimodal Profiling in Gastric Pre-Cancer	CI
02-18	Singular Genomics Launches G4X in the U.S., Delivering Throughput for in Situ Multiomics, Targets Translational and Clinical Applications	CI
27/02/25	Singular Genomics Systems, Inc. Announces Management Changes	CI
27/02/25	Dalen Meeter Resigns as CFO of Singular Genomics Systems, Inc	CI
22/02/25	Singular Genomics Systems, Inc. Announces Board Changes	CI
22/02/25	Singular Genomics Systems, Inc. Announces Chief Executive Officer Changes	CI
20/02/25	Singular Genomics Systems, Inc.(NasdaqCM:OMIC) dropped from NASDAQ Composite Index	CI
20/02/25	Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P., funds managed by Deerfield Management Company, L.P. Series C, completed the acquisition of the remaining 93.4% stake in Singular Genomics Systems, Inc. from a group of shareholders.	CI
20/02/25	Singular Genomics Systems, Inc.(NasdaqCM:OMIC) dropped from S&P TMI Index	CI
23/12/24	Singular Genomics Systems Agrees to Be Acquired By Deerfield Management for $20 per Share	MT
12/11/24	Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Reports Q3 Revenue $0.4M	MT

09/07/24	Goldman Sachs Adjusts Price Target on Singular Genomics Systems to $6.50 From $22.50, Maintains Neutral Rating	MT
15/05/24	Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.75 From $0.85, Maintains Neutral Rating	MT
20/03/24	UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating	MT
22/01/24	Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.85 From $0.95, Maintains Neutral Rating	MT
12/10/23	UBS Adjusts Singular Genomics Systems Price Target to $0.40 From $0.90, Maintains Neutral Rating	MT

24/02/25	Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT	AQ
21/02/25	Singular Genomics Announces Closing of Acquisition by Deerfield Management	AQ
21/01/25	SINGULAR GENOMICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Singular Genomics Systems, Inc. - OMIC	BU
06/01/25	SINGULAR GENOMICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Singular Genomics Systems, Inc. - OMIC	BU
23/12/24	Singular Genomics : Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share Form 8 K	PU

13/09/24	MÄRKTE USA/Weiter aufwärts - Goldpreis auf Allzeithoch
13/09/24	MÄRKTE USA/Weiter aufwärts - Adobe-Kurs knickt ein
13/09/24	MÄRKTE USA/Etwas fester - Spekulation über große Zinssenkung lebt wieder auf
13/09/24	MÄRKTE USA/Positive Stimmung an Wall Street dürfte anhalten
24/06/24	Borsa di Italia: L'Eurozona vuole evitare il suo momento Liz Truss

3 years	5.34	23.41
5 years	5.34	533.1
10 years	5.34	1,001.1

Singular Genomics Systems, Inc. Share Price

Stocks

OMIC

US82933R3084

Advanced Medical Equipment & Technology

Latest news: Singular Genomics Systems, Inc.

Analysts' recommendations: Singular Genomics Systems, Inc.

Press Releases: Singular Genomics Systems, Inc.

News in other languages: Singular Genomics Systems, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Singular Genomics Systems, Inc.

Latest insider transactions

Other Advanced Medical Equipment & Technology

Company Profile

Manager	Title	Age	Since
John Stark CEO	Chief Executive Officer	-	27/04/2026
Jyotsna Ghai COO	Chief Operating Officer	67	31/08/2023
Matthew Clawson IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Joshua Stahl BRD	Director/Board Member	40	20/02/2025
John Stark BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
21/02/25	Marcia Eisenberg	Issuer sale	Director	6,783	0.2674%
21/02/25	Kim Kamdar	Issuer sale	Director	22,139	0.8726%
21/02/25	Dalen Meeter	Issuer sale	Chief Financial Officer	32,790	1.2925%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SINGULAR GENOMICS SYSTEMS, INC.	+0.25%	-.--%	-	-	50.7M
THERMO FISHER SCIENTIFIC, INC.	+1.19%	+0.82%	+22.92%	+60.64%	256B
DANAHER CORPORATION	-0.42%	+3.46%	+4.97%	+23.48%	163B
INTUITIVE SURGICAL, INC.	-1.27%	+1.80%	-19.11%	+72.17%	155B
BOSTON SCIENTIFIC CORPORATION	-1.14%	-1.14%	-56.01%	-9.01%	65.3B
SIEMENS HEALTHINEERS AG	-0.04%	+0.60%	-14.12%	-8.32%	51.93B
EDWARDS LIFESCIENCES CORPORATION	+0.29%	+2.87%	+12.37%	+47.17%	52.35B
VEEVA SYSTEMS INC.	-1.48%	-1.63%	+6.01%	+65.40%	50.75B
AGILENT TECHNOLOGIES, INC.	+0.87%	+2.59%	+21.08%	+72.71%	50.04B
WATERS CORPORATION	+2.76%	+5.81%	+33.21%	+91.43%	46.03B
Average	+0.10%	+1.74%	+1.26%	+46.19%	98.94B
Weighted average by Cap.	+0.08%	+1.68%	+3.23%	+48.45%